Cleerly ISCHEMIA vs Study Watch

Cleerly ISCHEMIA offers a web-based platform with comprehensive, interactive reports and integrates with existing radiology reporting systems like PowerScribe via API, streamlining the workflow for clinicians. Patients only require a standard CCTA scan, simplifying their experience. While Verily Study Watch is designed for patient comfort as a wearable, the patient's direct interaction with the collected data is limited, with results primarily viewed by healthcare professionals via a web portal.

Cleerly ISCHEMIA provides immediate, actionable diagnostic and prognostic information for individual patient care, validated by multiple clinical trials demonstrating high accuracy for non-invasive ischemia detection and prediction of future adverse cardiovascular events. It directly aids in personalized diagnosis and treatment planning for heart disease and is billable under a Category I CPTu00ae code. Verily Study Watch, while collecting clinical-grade physiological data and having FDA clearance for ECG and irregular pulse monitoring, is primarily positioned as a tool for clinical research to generate real-world evidence and enable future solutions.

Cleerly ISCHEMIA, despite variable pricing by provider, has established Category I CPTu00ae codes for billing, indicating a defined pathway for reimbursement and integration into clinical financial models. Some public information suggests a retail price for its analysis. In contrast, Verily Study Watch's pricing is not publicly available and is primarily for clinical research and partnerships, making a direct comparison of its financial value in a standard clinical setting difficult.

Both tools are FDA-cleared, HIPAA compliant, and have BAAs. However, Cleerly ISCHEMIA explicitly details robust enterprise integration capabilities, including a web-based platform with secure data transfer via VPN or virtual appliance and API integration with systems like PowerScribe. While Verily Study Watch offers cloud-based data management and comprehensive support for research programs, the public mention of an ongoing (though denied) lawsuit regarding HIPAA/BAA compliance could introduce a perceived risk for some enterprises.

Cleerly ISCHEMIA demonstrates significant innovation by applying advanced AI to CCTA scans for non-invasive fractional flow reserve (FFR) estimation, vessel-level ischemia likelihood determination, and comprehensive coronary plaque characterization. This provides highly quantitative and prognostic insights that directly transform clinical decision-making for coronary artery disease. Verily Study Watch is also innovative as a multi-sensor wearable for continuous, real-world physiological data collection in research, enabling new digital biomarkers, but its impact is more foundational for future solutions.

Verily Study Watch offers more explicit and structured support resources, including dedicated 'Data Workbench resources' with forums, tutorials, and product documentation, as well as regulatory information PDFs and direct product support contacts. Verily also highlights 'high-touch assistance' from industry leaders and dedicated program managers for clients. Cleerly ISCHEMIA's available documentation appears more focused on billing guidelines and patient education, with less explicit detail on technical or developer support.